Your browser doesn't support javascript.
loading
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab.
Kearns, Jeffrey D; Wassmann, Paul; Olgac, Ufuk; Fichter, Marie; Christen, Brigitte; Rubic-Schneider, Tina; Koepke, Stephan; Cochin de Billy, Benjamin; Ledieu, David; Andre, Cedric; Hawtin, Stuart; Fischer, Benoit; Moretti, Francesca; Hug, Christian; Bepperling, Alexander; Brannetti, Barbara; Mendez-Garcia, Celia; Littlewood-Evans, Amanda; Clemens, Andreas; Grosskreutz, Cynthia L; Mehan, Pawan; Schmouder, Robert L; Sasseville, Vito; Brees, Dominique; Karle, Anette C.
Afiliação
  • Kearns JD; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Wassmann P; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Olgac U; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Fichter M; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Christen B; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Rubic-Schneider T; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Koepke S; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Cochin de Billy B; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Ledieu D; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Andre C; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Hawtin S; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Fischer B; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Moretti F; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Hug C; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Bepperling A; TRD Biologics and CGT, Novartis Pharma AG, Basel CH-4056, Switzerland.
  • Brannetti B; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Mendez-Garcia C; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Littlewood-Evans A; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Clemens A; Medical Affairs Region Europe, Novartis Pharma AG, Basel CH-4056, Switzerland.
  • Grosskreutz CL; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Mehan P; TRD Biologics and CGT, Novartis Pharma AG, Basel CH-4056, Switzerland.
  • Schmouder RL; Novartis Institutes for BioMedical Research, East Hanover, NJ 07960, USA.
  • Sasseville V; Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Brees D; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
  • Karle AC; Novartis Institutes for BioMedical Research, Basel CH-4056, Switzerland.
Sci Transl Med ; 15(681): eabq5068, 2023 02.
Article em En | MEDLINE | ID: mdl-36724241
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Análise de Causa Fundamental / Complexo Antígeno-Anticorpo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Sci Transl Med Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Análise de Causa Fundamental / Complexo Antígeno-Anticorpo Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Sci Transl Med Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos